Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Post Market Clinical Evaluation of Gamma 4

NCT: NCT05523635 · COMPLETED

NCT IDNCT05523635
StatusCOMPLETED
Start Date2023-03-06
Completion2025-10-16

Brief Summary

This is a prospective, multi-center, non-randomized, post-market clinical investigation of the Gamma 4 System. Neither subjects nor investigators are blinded to treatment. It is anticipated that a total of 100 subjects will be enrolled at five sites. Total duration of enrollment, 12 month follow-up and analysis is expected to take approximately 30 months. The clinical investigation has been designed to follow the surgeon's standard of care for subjects treated with a cephalomedullary nail for femoral fractures or and deformities, in addition to a 12 month follow-up visit. The primary endpoint of this clinical investigation is demonstration of bone consolidation by 12 months.

Frequently Asked Questions

What is Post Market Clinical Evaluation of Gamma 4?

Post Market Clinical Evaluation of Gamma 4 is a clinical trial registered under NCT05523635. Current status: COMPLETED.

What is the status of NCT05523635?

The current status of NCT05523635 (Post Market Clinical Evaluation of Gamma 4) is: COMPLETED.

When did Post Market Clinical Evaluation of Gamma 4 start?

Post Market Clinical Evaluation of Gamma 4 started on 2023-03-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.